Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Economic information and modeling report

Budget impact model

14 evidence topics · 14 sources

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.